Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2)
Positron emission tomography in multiple sclerosis - straight to the target
Julkaisun tekijät: Bodini Benedetta, Tonietto Matteo, Airas Laura, Stankoff Bruno
Kustantaja: NATURE PORTFOLIO
Julkaisuvuosi: 2021
Journal: Nature Reviews Neurology
Tietokannassa oleva lehden nimi: NATURE REVIEWS NEUROLOGY
Lehden akronyymi: NAT REV NEUROL
Volyymi: 17
Aloitussivu: 663
Lopetussivun numero: 675
Sivujen määrä: 13
ISSN: 1759-4758
eISSN: 1759-4766
DOI: http://dx.doi.org/10.1038/s41582-021-00537-1
Tiivistelmä
Following the impressive progress in the treatment of relapsing-remitting multiple sclerosis (MS), the major challenge ahead is the development of treatments to prevent or delay the irreversible accumulation of clinical disability in progressive forms of the disease. The substrate of clinical progression is neuro-axonal degeneration, and a deep understanding of the mechanisms that underlie this process is a precondition for the development of therapies for progressive MS. PET imaging involves the use of radiolabelled compounds that bind to specific cellular and metabolic targets, thereby enabling direct in vivo measurement of several pathological processes. This approach can provide key insights into the clinical relevance of these processes and their chronological sequence during the disease course. In this Review, we focus on the contribution that PET is making to our understanding of extraneuronal and intraneuronal mechanisms that are involved in the pathogenesis of irreversible neuro-axonal damage in MS. We consider the major challenges with the use of PET in MS and the steps necessary to realize clinical benefits of the technique. In addition, we discuss the potential of emerging PET tracers and future applications of existing compounds to facilitate the identification of effective neuroprotective treatments for patients with MS.In this Review, Bodini et al. discuss the contribution that PET is making to our understanding of mechanisms involved in the pathogenesis of irreversible neuro-axonal damage that underlies progression in multiple sclerosis.
Following the impressive progress in the treatment of relapsing-remitting multiple sclerosis (MS), the major challenge ahead is the development of treatments to prevent or delay the irreversible accumulation of clinical disability in progressive forms of the disease. The substrate of clinical progression is neuro-axonal degeneration, and a deep understanding of the mechanisms that underlie this process is a precondition for the development of therapies for progressive MS. PET imaging involves the use of radiolabelled compounds that bind to specific cellular and metabolic targets, thereby enabling direct in vivo measurement of several pathological processes. This approach can provide key insights into the clinical relevance of these processes and their chronological sequence during the disease course. In this Review, we focus on the contribution that PET is making to our understanding of extraneuronal and intraneuronal mechanisms that are involved in the pathogenesis of irreversible neuro-axonal damage in MS. We consider the major challenges with the use of PET in MS and the steps necessary to realize clinical benefits of the technique. In addition, we discuss the potential of emerging PET tracers and future applications of existing compounds to facilitate the identification of effective neuroprotective treatments for patients with MS.In this Review, Bodini et al. discuss the contribution that PET is making to our understanding of mechanisms involved in the pathogenesis of irreversible neuro-axonal damage that underlies progression in multiple sclerosis.